

Wondfo Rapid One Step Test HIV1/2 (2 lines)

Presenter:
Carol Leong
Application Specialist

Scan Me for Attendance:





Scan & Download









About Us

Medical Innovation Ventures Sdn. Bhd. (Mediven®) specialises in the design, development and manufacturing of infectious disease *in vitro* diagnostics products.

Company	Medical Innovation Ventures Sdn. Bhd.
Founded in	2012
Address	1st Floor, Plot 88f, Lintang Bayan Lepas 10, Bayan Lepas Industrial Park, Bayan Lepas Free Industrial Zone Phase 4, 11900 Bayan Lepas, Pulau Pinang, Malaysia.
Website	www.mediven.com.my





About Us

- One of the few fully integrated IVD specialists based in ASEAN.
- Our products are validated by independent International External Quality Assessment (EQA) from the UK and Australia.





Key Milestones

- CE-IVD granted for 32 immunoassays (ProDetect[®]).
- CE-IVD marks obtained for 18 molecular diagnostics (GenoAmp®).
- Sole supplier of HIV rapid tests to Malaysia government hospitals
- Sole supplier of Dengue rapid tests to Brunei government hospitals











Our Products



Infectious Diseases

- Respiratory infection
- Tropical fever
- Sexually Transmitted Infection



Toxicology

- Workplace
- Government
- Reference Lab




Family Health

- Women's Health
- Oncology



ProDetect® Rapid Test Platform



Private & Confidential



GenoAmp® Platform

Real-Time PCR

- Multiplex detection of pathogens in a single tube
- Detection through real-time PCR
- Easy reaction setup

Viral Respiratory Panel

- FluA/H1N1/H3 N2/FluB
- MERS-CoV
- Flu/MERS/ SARS-CoV-2
- SARS-CoV-2

Bacterial Respiratory Panel

 Bordetella pertussis

Tropical Fever Panel

- Dengue 1-4
- Chikungunya
- Zika
- Dengue/Chikun gunya/Zika
- Leptospirosis
- Malaria
- Malaria/Leptos pirosis/Salmone lla/B. pseudomallei

TB Panel

MTBC/NTM

Endpoint

- Vibrio Cholera
- MTBC/NTM




- 1 Introduction of HIV
 - 2 Principle of RTK
- 3 Specimen Collection
- Test Procedure and Results Interpretation
- 5 IMR and WHO Report



Introduction to HIV

- HIV (human immunodeficiency virus) is a RNA virus that attacks the body's immune system.
- It is spread through a specific type of cell called CD4 cells, also known as T-cells. These special cells help the immune system fight off infections.
- If left untreated, HIV will reduces the number of CD4 cells (T-cells) in the body, damaging the immune system.
- Eventually, this will lead to AIDS (acquired immunodeficiency syndrome), which also makes it easier for infections or cancers to take advantage of a very weak immune system and cause death.





HIV Types

CHARACTERISTICS	HIV-1	HIV-2	
Infectivity	High		
Virulence	High	Low	
Heterosexual Spread	Higher	Lower	
Vertical Transmission	20-25%	≤5%	
Genetic Diversity	_	Lower	
Prevalence	Global	West Africa	
Origin	Common Chimpanzee	Sooty Mangabey	
Time to Aids	≤10 Years	≥20 Years	



HIV Transmission



HIV/AIDS

HIV is transmitted



use of non-sterile syringes and tools



pregnancy breastfeeding



blood transfusion



organ transplant



unprotected sex

HIV is not transmitted



food, drink, utensils



insect bites



kiss, touch



clothes, towels



toilet, shower



Stages of HIV

WHAT ARE THE STAGES OF HIV?



ACUTE HIV

flu-like symptoms that occur days to weeks after contracting HIV

2

CHRONIC HIV

also known as the latent or asymptomatic stage; can last for several years



AIDS

occurs when CD4
cell count falls
below 200
cells/mm3;
makes a person
vulnerable to
opportunistic
infections and
AIDS-defining
conditions

healthline




Statistic of HIV in Malaysia



2022 GLOBAL AIDS MONITORING

Country Progress Report -Malaysia





Overview of HIV & AIDS Epidemic in Malaysia (2021)

2,760

New HIV infections in 2021

67,822

Total people living with HIV (1986 – 2021)

10

New HIV infections in children (<13 years old) in 2021 128,638

Total reported HIV cases (1986 – 2021)

8.5

HIV notification rate in 2021 (per 100,000 people)

1,219

Total reported HIV in children (<13 years old) (1986-2021)

519

AIDS-related deaths in 2021

279

New HIV infections in women & girls in 2021

68,956

Total reported HIV in people who inject drugs (1986-2021)

45,969

Total reported AIDS-related deaths (1986 – 2021)

14,492

Total reported HIV in women & girls (1986 – 2021)

48,288


Total reported cases of sexually transmitted HIV (1986-2021)

Source: HIV/STI Sector, Division of Disease Control, Ministry of Health Malaysia



Current HIV Trend in Malaysia

NEW HIV CASES (1986-2021)






Impact of COVID-19 pandemic on HIV management in Malaysia

- In 2021, Malaysia did not meet the fast-track targets for Ending AIDS, despite previous successes.
- COVID-19 pandemic disrupted community-based HIV screening and prevention activities.
- COVID-19 pandemic also affected the distribution of health workers in places they are needed the most.
- Prolonged movement control orders and various nonpharmacological prevention strategies such as physical distancing, limitations in face-to-face consultations restricted PLHIVs' access to health care and other social support.



Statistic of HIV in Malaysia



New HIV infections are mainly contributed by patients in the age group of 20-29 and 30-39.


(% of 2,760 new infections)



Statistic of HIV in Malaysia

HIV TRANSMISSION BY RISK FACTOR IN 2021

Most common mode of HIV transmission in Malaysia in 2021 is sexual transmission.



*Include blood transfusions, organ transplantations, needle stick injuries and no information.

(% of 2,760 new infections)



Changes in mode of transmission over the last 2 decades

COMPARISON OF NEW HIV INFECTIONS BETWEEN INJECTING DRUG USERS (IDU) & SEXUAL TRANSMISSION (2005-2021)

Mode of transmission for HIV changes from predominantly IDU to sexual transmission. The proportion of sexual transmission has increase to 96% in 2021


60%

40%

20%

25%

65%




2021



HIV Cases in Malaysian States


Figure 4: People living in HIV in Malaysia by state, 2021






MEDIVEN Window Period of HIV/AIDS

- After exposure to HIV, there will be biomarkers in the blood of the patients such as HIV RNA, HIV antibody, HIV antigen p24.
- From the day of exposure to the day where these biomarkers are detectable, it is called window period.






Window Period of HIV/AIDS





HIV Infection & Laboratory Markers



Source: Grant, Robert & Smith, Dawn. (2015). Integrating antiretroviral strategies for HIV prevention: post- and pre-exposure prophylaxis, and early treatment. Open Forum Infectious Diseases. 2. ofv126. 10.1093/ofid/ofv126.



HIV Detection Methods

Nucleic Acid Test (NAT)*

window period

10-33 days

Antigen/Antibody Lab Test*

window period

18-45 days

Rapid Antigen/Antibody Test[†]

window period

18-90 days



Antibody Test*

window period

23-90 days



- * Performed by a lab on blood from a vein.
- † Done with blood from a finger stick.
- ‡ Most rapid tests and self-tests are antibody tests.



HIV Diagnosis

HIV Test
Pre-Test
Post-Test



Pre-Test

Risk assessment

Assessment of behavioral risk

Five P's approach

- Partner
- Practice
- Protection
- Past history
- Pregnancy

Assessment of biologic risk

Test for the presence of anti-HIV antibody






Product Specification



Product Name	Mediven Wondfo One Step HIV1/2 Test			
Product Code	W6-C			
Technology	Rapid Immunochromatographic Direct Binding			
Packing	20 individually packed tests/box			
Target	HIV antibody			
Sample	Whole Blood/Serum/Plasma			
Incubation Time	15 mins			
Result	Qualitative: Positive/Negative			
Sensitivity	99.10%			
Specificity	99.20%			
Storage	Room temperature. Do not freeze. Avoid sunlight, moisture and heat.			
Shelf Life	24 months from manufacturing date			




Wondfo HIV1/2 Rapid Test





How Rapid Immunochromatographic Direct Binding Work?

Lateral flow



Process:

- The test strip contains antigen conjugated to colloidal gold, synthetic HIV antigens and immobilized anti-human antibody.
- When sample containing HIV antibody is drop onto the test strip, it binds to antigen conjugated with colloidal gold forming antigen-HIV antibody complex.
- 3. The flow continues, antigen-HIV antibody complex will bind to the synthetic HIV antigens.
- The flow continues, immobilized anti-human antibody will capture the non specific human antibody.
- 5. Accumulation of colloidal gold at the control and test lines creates a reddish-purple stripe.









Synthetic HIV antigen

HIV antibody (from specimen)

Immobolized antihuman antibody Antigen conjugated to colloidal gold

Source: Hurt CB, Nelson JAE, Hightow-Weidman LB, Miller WC. Selecting an HIV Test: A Narrative Review for Clinicians and Researchers. Sexually Transmitted Diseases. 2017 Dec;44(12):739-746. DOI: 10.1097/olq.00000000000000719. PMID: 29140890; PMCID: PMC5718364.



Specimen Collection

Whole blood



Heparin tube EDTA tube Sodium citrate tube

Serum & Plasma



- Recommended: specimen should be used immediately after collection
- If not tested immediately:
 May be stored at 2-8°C for not more than 7 days

- Separate the serum/plasma from blood as soon as possible to avoid hemolysis
- Recommended: specimen should be used immediately after collection
- If not tested immediately: May be stored at 2-8°C up to 3 days
- Long term storage:
- Below -20°C

Bring specimens to room temperature before testing



Specimen Collection

Fingerstick

- Select the finger for puncture
- Clean the area to be lanced with an alcohol pad and allow finger to dry.
- Using a sterile lancet, puncture skin just off centre of finger
- Apply gentle pressure to finger
- Wipe away 1st drop of blood
- Allow a new drop of blood to form
- Take the dropper provided, while gently squeezing the tube, immerse the open end in the blood drop and gently release the pressure.
- Whole blood samples collected by fingerstick should be used immediately





MEDIVEN Test Procedure and Results Interpretation

- 1. Remove a test cassette from the foil pouch by tearing at the notch and place it on a level surface.
- Squeeze the pipette gently before placing the tip of pipette to the blood drop.




3. Slowly release the pressure on the pipette and draw the blood slowly into the pipette until it reaches the second mark line.



MEDIVEN Test Procedure and Results Interpretation


Slowly add 10 µl of specimen to the sample well (A) and then add 2 drops of dilution buffer to the buffer well (B).



- 5. Wait for 15 mins and read the results.
- Discard the results after 30 mins. 6.




MEDIVEN Test Procedure and Results Interpretation




Positive (+) / Reactive

- Rose-pink bands are visible in both the C and T regions.
- Indicates presence of HIV1/2 is equal to/ higher than the detection limit of the test



Negative (-) / Non-Reactive

- Rose-pink band is visible in C region.
- No colour band appears in T region.
- Indicates that concentration of HIV1/2 Ab is zero/below the detection limit of the test.



Invalid

- No visible band at all, or there is a visible band only in the T region (not in C region)
- Repeat with a new test device.
- If test still fails, please contact the distributor/store with the lot number



Post-Test

Negative

High risk patient

Retest after eclipse period/window period

Positive

Proceed with validation/confirmation test

 ELISA, Western blot or PCR



IMR Performance Report

		True HIV status of panel sera			
		HIV-1 Positive	HIV-1 Negative	Total	
Wondfo One Step HIV 1/2	Positive	100	0	100	
	Negative	0	100	100	
	Total	100	100	200	

- The evaluation was performed on 200 well characterized samples; 100 positive known HIV individuals and 100 HIV negative individuals.
- Test kit has correctly identified all the 100 HIV-1 Ab positive sera and 100 HIV-1 Ab negative sera.
- Sensitivity 100.0%, specificity 100.0%
- Results obtained also indicate that the kit produces an estimated value of 100.0% for PPV (probability that the serum does contain HIV Ab when test is positive) and 100.0% NPV (probability that the serum does not contain HIV Ab when the test is negative).



WHO Report

Assay (manufacturer)	Report No a	Sensitivity (%) ^{b, c}	Specificity (%) ^{çd}	Inter-reader variability %
Retrocheck HIV WB / Core HIV 1&2 (Qualpro Diagnostics / Core Diagnostics)	16	100 (98.8–100)	99.1 (97.8–99.8)	0.4
Alere Determine™ HIV-1/2 (Alere Medical Co. Ltd)	17	100	98.9	1.4
HIV 1/2 STAT-PAK® (Chembio Diagnostic Systems, Inc.)	17	99.5 (98.3–99.9)	100 (99.4–100)	0.2
HIV 1/2 STAT-PAK® Dipstick (Chembio Diagnostic Systems, Inc.)	17	100 (29.1–100)	99.7 (98.9–99.9)	0.1
One Step HIV 1/2 Whole Blood/Serum/ Plasma Test (Guangzhou Wondfo Biotech Co., Ltd)	17	100 (99.1–100)	99.9 (99.2–100)	0.2
Uni-Gold™ HIV (Trinity Biotech Manufacturing Ltd)	17	99.8 (98.7–100)	99.9 (99.2–100)	0.1
Anti-human immunodeficiency virus (HIV) antibody diagnostic kit (colloidal gold) (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd)	17	100 (99.1–100)	98.5 (97.2–99.3)	0.1
INSTI HIV-1/HIV-2 Antibody Test (bioLytical Laboratories)	17	100 (99.1–100)	99.7 (98.9–100)	0.0
Reveal Rapid HIV Antibody Test (MedMira Laboratories Inc)	17	99.8 (98.6–100)	99.9 (99.2–100)	1.6



Certifications

MDA

FDA 21 CFR 820

ISO 9001:2008 ISO 13485:2003

CE















Product Video






THANK YOU

Technical Supports

Carol Leong
Application Specialist
carol@mediven.com.co

Scan Me for Attendance:



Contact us



Email (for Malaysia Market)

sales@mediven.com.co



Email (for Export Market)

export@mediven.com.co



Phone

+604-6562824



How to get your E-certificate?



WHO is MyDocLab™

A one stop digital lifestyle healthcare app to manage your everyday healthcare needs.





A digital healthcare platform where users can manage their self health-status on-the-go.




CONVENIENT

SAVE TIME

AFFORDABLE



How to get your E-certificate?





How to get your E-certificate?

